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the role of membrane excitability 
in pancreatic β-cell glucotoxicity
Zeenat A. shyr1, Zhiyu Wang1,4, Nathaniel W. York2, Colin G. Nichols  2,3 & 
Maria s. Remedi1,2,3
persistent hyperglycemia is causally associated with pancreatic β-cell dysfunction and loss of 
pancreatic insulin. Glucose normally enhances β-cell excitability through inhibition of KAtp channels, 
opening of voltage-dependent calcium channels, increased [Ca2+]i, which triggers insulin secretion. 
Glucose-dependent excitability is lost in islets from KAtp-knockout (KAtp-Ko) mice, in which β-cells 
are permanently hyperexcited, [Ca2+]i, is chronically elevated and insulin is constantly secreted. 
Mouse models of human neonatal diabetes in which KAtp gain-of-function mutations are expressed 
in β-cells (KAtp-GoF) also lose the link between glucose metabolism and excitation-induced insulin 
secretion, but in this case KAtp-GoF β-cells are chronically underexcited, with permanently low [Ca2+]i 
and lack of glucose-dependent insulin secretion. We used KAtp-GoF and KAtp-Ko islets to examine 
the role of altered-excitability in glucotoxicity. Wild-type islets showed rapid loss of insulin content 
when chronically incubated in high-glucose, an effect that was reversed by subsequently switching 
to low glucose media. In contrast, hyperexcitable KAtp-Ko islets lost insulin content in both low- and 
high-glucose, while underexcitable KAtp-GoF islets maintained insulin content in both conditions. 
Loss of insulin content in chronic excitability was replicated by pharmacological inhibition of KAtp by 
glibenclamide, The effects of hyperexcitable and underexcitable islets on glucotoxicity observed in in 
vivo animal models are directly opposite to the effects observed in vitro: we clearly demonstrate here 
that in vitro, hyperexcitability is detrimental to islets whereas underexcitability is protective.
In the pancreatic β-cell, ATP-sensitive K+ (KATP) channels play a critical role in coupling glucose metabolism to 
insulin secretion via control of membrane excitability, thereby maintaining blood glucose within a narrow phys-
iologic range1. Increase in glucose metabolism leads to elevated intracellular ATP/ADP ratio and closure of KATP 
channels, with consequent membrane depolarization, leading to opening of voltage-dependent calcium channels 
and increased [Ca2+]i, which in turn triggers insulin secretion. Conversely, decrease in the metabolic signal opens 
KATP channels and suppresses the electrical trigger for insulin secretion1. Normally, the β-cell responds to chronic 
high glucose with a compensatory increase in β-cell mass to match the insulin secretory requirement. However, 
in genetically or otherwise predisposed individuals, β-cells are unable to sustain appropriate insulin secretory 
response and diabetes develops2. Persistent hyperglycemia may also lead to β-cell dysfunction and loss of insulin 
content3. Underlying mechanisms of this so-called glucotoxicity remain unclear, but the unique capacity of β-cells 
to increase oxidative phosphorylation in response to glucose availability makes them prone to increased reactive 
oxygen species production, which may underlie increased levels of oxidative stress markers and augmented apop-
totic cell-death found in islets from type-2 diabetic organ donors4–7.
The importance of electrical activity in β-cell function is highlighted by the fact that KATP gain-of-function 
(GOF) mutations cause human Neonatal Diabetes Mellitus (NDM)8, KATP GOF polymorphisms are highly asso-
ciated with type-2 diabetes9, and KATP loss-of-function (LOF) mutations underlie congenital hyperinsulinism 
(CH) (reviewed in1,10,11). Mouse models of NDM and CH due to genetically altered β-cell membrane excitability 
have been generated12–19. As expected, KATP-GOF mice, with underexcitable β-cells and permanently low [Ca2+]i, 
show low circulating insulin levels and develop diabetes12,20. Importantly, as diabetes progresses, KATP-GOF mice 
demonstrate a marked loss of insulin content, a typical secondary consequence of glucotoxicity12. However, the 
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paradigmatic understanding that this glucotoxic loss of insulin content is the result of β-cell death is challenged by 
the demonstration of β-cell dedifferentiation, with no significant increase in apoptosis in pancreases from either 
diabetic mice or human type-2 diabetic organ donors21–23. Critically, we have demonstrated that this loss of β-cell 
mass in KATP-GOF mice is caused by loss of mature β-cell identity and dedifferentiation to neurogenin3+/insulin 
negative cells, rather than apoptotic cell death22.
Chronic hyperglycemia will lead to hyperstimulated metabolism, which will be constitutively coupled to 
hyperexcitability and chronically elevated [Ca2+]i, factors that have all been suggested to play a role in diabetic 
loss of β-cell function (Fig. 1). Moreover, decreased insulin secretion and mRNA and increased β-cell death have 
been demonstrated in multiple in vitro studies2,3,24,25. However, KATP-LOF and KATP-knockout (KO) mice, with 
chronically hyperexcitable β-cells and persistently elevated [Ca2+]i, do not show any obvious changes in insulin 
content or β-cell mass15,16,18,26,27, and KATP-KO islets have been reported to be less susceptible to the toxic effects 
of high glucose, oxidative stress and death28. Conversely, as discussed, there is dramatic secondary loss of insulin 
content in KATP-GOF mice that is not predicted as a direct consequence of their permanent underexcitability and 
low [Ca2+]i.
In this study, we sought to determine the role of excitability in glucotoxic β-cell failure, and to ask whether this 
glucotoxicity is induced by hypermetabolism per se, or by the normally obligatorily coupled hyperexcitability and 
high [Ca2+]i. To do this, we have examined insulin content and secretion under glucotoxic conditions in islets iso-
lated from mice in which the link between β-cell metabolism and excitability is lost. We have achieved this both 
genetically, using (i) islets from KATP-GOF mice with underexcitable β-cells and permanently low [Ca2+]i, and (ii) 
from KATP-KO mice with hyperexcitable β-cells with chronically elevated [Ca2+]i (Fig. 1), and pharmacologically 
by treatment of wild type islets with chronic KATP channel activator (diazoxide) or inhibitor (glibenclamide). We 
demonstrate that underexcitability is protective against glucotoxic conditions in vitro, while hyperexcitability 
induces loss of insulin content even under low-glucose conditions. These results do not correlate with those 
obtained in vivo, where animal models of altered β-cell excitability show the opposite effects, highlighting the 
importance of whole body physiology.
Results
Morphological changes induced by high glucose in islets with normal or altered membrane 
excitability. To directly test the influence of membrane excitability on glucotoxicity in β-cells, islets with 
normal (wild-type, KATP-WT), or with genetically increased- (Kir6.2 knockout: KATP-KO) or decreased-mem-
brane excitability (Pdx-Cre/Kir6.2[K185Q, ΔN30] gain-of-function: KATP-GOF) were isolated from adult mice 
and chronically incubated in low (3 mM) or high (30 mM, mimicking the glucose concentration that islets are 
exposed in KATP-GOF mice) glucose for up to two weeks. Independent of the glucose concentration, or the genet-
ically altered membrane excitability, the number of intact islets remaining in the dish did not change significantly 
over the period of time tested (at time 0: 30 ± 0 islets/dish on each genotype, after 10 day incubation: KATP-WT: 
27.4 ± 0.91 islets/dish, KATP-GOF: 25.8 ± 1.2 islets/dish and KATP-KO: 24.6 ± 1.6 islets/dish). However, KATP-WT 
islets exposed to chronic high glucose became noticeably more translucent than islets incubated in low glucose 
(Fig. 2a,b) and were larger in diameter (Fig. 2c). KATP-KO islets (with increased membrane excitability) incubated 
in low glucose were more translucent at low or high glucose compared to control and KATP-GOF islets under the 
same conditions (Fig. 2a,b). Conversely, islets from KATP-GOF mice (with decreased excitability) maintained their 
morphology and diameter (Fig. 2) suggesting that membrane underexcitability is protective.
electrophysiology of islets chronically incubated in low and high glucose. We performed current 
clamp recordings of membrane potential and voltage clamp recording of membrane conductance and capaci-
tance using β-cells isolated from KATP-WT islets chronically incubated in low and high glucose. Figure 3 shows 
representative traces (a) and averages (b) of the membrane potential of β-cells (i) chronically incubated in low 
(3 mM) glucose following break-in in 1 mM glucose (blue), or (ii) chronically incubated in high (30 mM) glucose 
Figure 1. Schematic representation of the proposed key factors involved in pancreatic β-cell damage. In type-2 
diabetes, hyperglycemia-induced hypermetabolism is constitutively coupled to membrane hyperexcitability, 
high [Ca2+]i and insulin hypersecretion but in KATP-LOF (congenital Hyperinsulinism) or KATP-KO mice 
hypermetabolism is uncoupled from hyerexcitability and high [Ca2+]i, which are persistently high in these mice. 
Conversely, in KATP-GOF induced neonatal diabetes, hyperglycemia-induced hypermetabolism is uncoupled 
from hyerexcitability and high [Ca2+]i since they are constitutively low in these mice. Grey boxes represent the 
initial changes, and some of them have been attributed to cause beta-cell damage, as pointed by red arrows.
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following break-in in 10 mM glucose (orange). As predicted for normal KATP behavior, the first are hyperpo-
larized (mean Vm = −64 ± 2 mV) due to active KATP channels (blue), whereas the second are depolarized 
(mean Vm = −49 ± 4 mV), but then hyperpolarize as KATP spontaneously activates following break-in (orange). 
Figure 3c shows voltage-clamp recording of membrane currents in response to voltage ramps (from −120 to −40 
mV) from a cell chronically incubated in low (3 mM) glucose after break-in (in 1 mM glucose, blue), then after 
with spontaneous activation to maximum KATP (orange), then following subsequent KATP rundown (grey). The 
average maximum KATP current density in cells chronically incubated in 3 or 30 mM glucose is shown in Fig. 3d. 
KATP currents are present in both after the 10 day incubation period, although smaller in cells chronically incu-
bated in high glucose. Figure 3e shows that cell capacitance, directly related to cell surface area, is approximately 
Figure 2. Islet Morphology. (a) Representative picture of pancreatic islets from KATP-WT or genetically altered 
mice 9 days after incubation in low or high glucose. (b) Quantification of mean gray values (A.U) for islet 
translucency on KATP-WT (black), KATP-KO (red) or KATP-GOF (green) islets chronically incubated in low- or 
high-glucose. n = 3 experiments from 9 independent mice, experiments were done in triplicates. Significant 
differences *p < 0.05, **p < 0.01, ***p < 0.001 and ****p < 0.0001 under the same condition; non-significant 
differences are not indicated in the figure. (c) Quantification of islet area (mm2) on KATP-WT (black), KATP-KO 
(red) or KATP-GOF (green) islets chronically incubated in low- or high-glucose. n = 3 experiments from 9 
independent mice, experiments were done in triplicates.
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doubled in cells from islets chronically incubated in high glucose, correlating with the observed increased in islet 
area (Fig. 2c).
Insulin content in islets from genetically altered mice chronically exposed to high glucose. 
KATP-WT islets incubated in high glucose demonstrated a marked and rapid reduction of initial insulin content 
(to ~40%), over the first 3 days, which was subsequently maintained with no further decline over longer incuba-
tion times (Fig. 4a, black circles and squares, solid lines). This early reduction in insulin content was dramatically 
reversed in islets that were switched back to low glucose after 3 days incubation in high glucose, indicating a 
reversible effect with no permanent damage (Fig. 4a, black dashed line). Conversely, KATP-WT islets incubated 
in low glucose showed only a minimal reduction of insulin content over a period of 10 days. Strikingly, islets 
from KATP-KO mice (with increased membrane excitability and chronically elevated [Ca2+]i16) also demonstrated 
a rapid (3 days) reduction of insulin content to a similar plateau as KATP-WT islets, independent of whether 
incubated in low or high glucose (Fig. 4a, red circles and squares, solid lines). The reduction in insulin content 
observed in KATP-KO islets at low glucose was slightly greater when incubated in high glucose, and again this was 
reversed to the level maintained in low glucose when the media was switched from high to low glucose (Fig. 4a, 
red dashed line).
As we previously described, KATP-GOF mice (with reduced β-cell excitability12 and chronically low [Ca2+]i20), 
demonstrate severe diabetes within 2 weeks of tamoxifen induction of transgene expression. In vivo, this 
Figure 3. Beta-cell electrophysiology. (a) Representative traces of membrane potential during current clamp 
recordings from β-cells of KATP-WT islets chronically incubated in 3 mM glucose (blue) or 30 mM glucose 
(orange) in bath solution containing 1 mM or 10 mM glucose, respectively. (b) Average membrane potential 
upon break into β-cells from islets chronically incubated in 3 mM or 30 mM glucose. (c) Representative traces 
of current density in β-cell from islets chronically incubated in 3 mM glucose showing break-in current (blue), 
current at maximal KATP activation (orange) and current after KATP rundown (grey). (d) Average current density 
at −120 and −40 mV during maximal KATP activation is shown from islets chronically incubated at 3 mM 
(n = 13, blue) and 30 mM (n = 23, orange) glucose. (e) Capacitance of β-cells from islets chronically incubated 
in 3 mM (blue) and 30 mM (orange) glucose.
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is followed by reduction in β-cell mass and insulin content due to dedifferentiation from mature β-cells to 
progenitor-like cells, secondary consequences of chronic systemic diabetes12,22, which include correlate loss of 
insulin and elevation of glucose. To specifically isolate the influence of electrical activity in glucotoxic condi-
tions, islets from KATP-GOF mice were harvested 10 days after tamoxifen-induction (i.e. prior to development 
of secondary consequences)12 and then chronically incubated in low or high glucose in vitro. In contrast to WT 
and KATP-KO islets, insulin content of KATP-GOF islets was completely preserved at low glucose, and only slightly 
reduced at high glucose (Fig. 4a, green circles and squares, solid lines), and again was completely reversed by 
switching the media from high to low glucose (Fig. 4a, green dashed line). These results indicate that membrane 
Figure 4. Glucotoxic changes in islet insulin content in vitro depend on membrane excitability. (a) Insulin 
content over time in islets from KATP-WT (black), KATP-KO (red) or KATP-GOF (green) mice chronically 
incubated in 3 mM (circles, solid line) or 30 mM (squares, solid line) glucose, or when media has been switch 
from high to low glucose (dashed lines). n = 3 experiments from 6 independent mice, experiments were done 
in triplicates. Significant differences *p < 0.05 respect to control under the same condition; non-significant 
differences are not indicated in the figure. (b) Total insulin content per islet at day 0 of incubation from 
KATP-WT (black), KATP-KO (red) or KATP-GOF (green) mice. (c) Insulin secreted into the media from KATP-WT 
(black), KATP-KO (red) or KATP-GOF (green) islets chronically incubated in 3 mM or 30 mM glucose at day 3.
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underexcitability protects from loss of insulin content in these glucotoxic conditions. KATP-WT, KATP-GOF and 
KATP-KO islets all had similar total islet insulin content on day 0 (Fig. 4b). As predicted, islets from KATP-KO 
mice demonstrate insulin hypersecretion when chronically incubated in low (3 mM) glucose, while KATP-WT 
and KATP-GOF do not secrete insulin in this condition (Fig. 4c, left). Moreover, while islets from KATP-WT mice 
secrete insulin when incubated in 30 mM glucose media, KATP-GOF show blunted secretion due to the mutation 
as expected (Fig. 4c, right).
High glucose effect on islets with pharmacologically altered membrane excitability. An alter-
native approach to manipulate membrane excitability is pharmacologically. WT islets were chronically incubated 
with the sulfonylurea glibenclamide (KATP channel inhibitor) to increase membrane excitability, or with diazoxide 
(KATP channel activator) to decrease membrane excitability, in parallel to the genetic approach above. As above, 
WT islets chronically incubated in high glucose demonstrated a marked decrease in insulin content compared to 
islets incubated in low glucose (Fig. 5a). Glibenclamide treatment caused a significant loss of insulin content in 
WT islets incubated in either low or high glucose (Fig. 5a). Conversely, diazoxide-treatment of WT islets resulted 
in preservation of insulin content in both low and high glucose conditions (Fig. 5a). These results mirror those 
obtained from KATP-KO and KATP-GOF islets, respectively (Fig. 4). To examine the consequences of insulin deple-
tion per se in these experiments, exogenous insulin was added to WT islets incubated in low and high glucose. We 
demonstrate here that insulin prevented the high glucose-induced loss of insulin content (Fig. 5a).
Effects of chronic pharmacologically increased or decreased excitability on glucose-dependent 
insulin secretion. We examined the insulin secretory response to glucose challenge in WT islets incubated 
for 10 days in low or high glucose, in the absence or presence of KATP channel inhibitors or activators. WT islets 
chronically incubated in low glucose secreted insulin normally in response to acute high glucose stimulation 
(Fig. 5b). However, WT islets that had been chronically incubated in high glucose showed an unexpectedly high 
basal insulin secretion in response to acute low glucose, but blunted response to acute high glucose (Fig. 5c). 
Importantly, WT islets chronically incubated in low or high glucose in the presence of glibenclamide also showed 
increased insulin secretion when acutely exposed to low glucose (Fig. 5b), and a marked decrease in insulin secre-
tion when exposed to high glucose for one hour (Fig. 5c). Conversely, islets chronically incubated with diazox-
ide (KATP activator, which results in electrical ‘rest’) demonstrated both increased basal and glucose-stimulated 
insulin secretion, compared to islets exposed to glucose alone (Fig. 5b,c). When insulin secretion was calculated 
as a fraction of insulin content, it is clear that chronic glibenclamide acutely stimulates increased basal secretion, 
whereas diazoxide inhibits glucose-dependent secretion, in both cases (Fig. 5b,c, inserts).
proinsulin is increased in islets exposed to chronic high glucose. Because of the dramatic decrease 
in insulin content, we tested whether proinsulin biosynthesis was altered in genetically altered or pharmacolog-
ically treated islets. All islets exposed to chronic high glucose demonstrated a significant increase in proinsulin 
content, independent of the genotype (Fig. 6a) or pharmacologic treatment (Fig. 6b). At time 0, KATP-KO islets 
showed lower proinsulin content than WT (Fig. 6a, red circles and squares), whereas KATP-GOF islets demon-
strated a markedly higher proinsulin level (Fig. 6a, green circles and squares). Conversely, all islets exposed to 
chronic low glucose demonstrated a significant decrease in proinsulin content over time, independent of the 
genotype (Fig. 6a) or pharmacologic treatment (Fig. 6b). These results demonstrate quite clearly that there is a 
positive effect of high glucose on proinsulin content, irrespective of membrane excitability.
Discussion
Chronic effects of hyperglycemia on islet function. Progressive deterioration in β-cell function, 
increased levels of oxidative stress markers, loss of insulin content and decreased β-cell mass in vivo have long 
been recognized in the pathogenesis of type-2 diabetes4–6,24, regardless of therapy7,29. Chronic hyperglycemia 
and elevated free fatty-acids negatively impact β-cell function and insulin secretion, but mechanisms underlying 
secondary loss of insulin remain unclear. In otherwise normal islets, chronic hyperglycemia will cause a persis-
tent increase in membrane excitability and permanently elevated [Ca2+]i, potential key factors in deterioration 
of β-cell function ultimately leading to β-cell death30,31. However, this paradigm of β-cell death in diabetes has 
now been challenged by the demonstration of loss of pancreatic β-cell identity and cell dedifferentiation in both 
mouse and human diabetes21–23,32. The largely unknown and potentially detrimental effects of abnormally high or 
low [Ca2+]i prompts us to ask the question: What role does membrane hyper- or hypo-excitability per se, and the 
consequently high or low [Ca2+]i, play in the deleterious effects of high glucose on islet function. By incubating 
islets from mice with genetically enhanced or reduced membrane excitability (i.e. KATP-KO and KATP-GOF mice 
respectively) in chronic high glucose in vitro, we can separate the role of excitability from otherwise linked in vivo 
factors in any glucotoxic response.
the role of membrane excitability in glucotoxicity. The unique capacity of β-cells to increase oxida-
tive phosphorylation in response to glucose availability makes them prone to increased reactive oxygen species 
production, which may lead to mitochondrial dysfunction and ultimately cell death. In WT islets, the marked 
reduction of insulin content and glucose-stimulated insulin secretion (GSIS) when chronically incubated in 
high glucose is consistent with earlier studies demonstrating that rodent β-cells adapt to chronic high glucose by 
reducing maximal GSIS, but without alterations in pancreatic islet mass33. The maintenance of insulin content 
in KATP-GOF islets exposed to high glucose indicates that reduced membrane excitability protects them against 
such a loss of insulin content in vitro. In addition, this finding argues against any primary role of underexcitability 
and low [Ca2+]i20 in the loss of β-cell mass and especially insulin content that are observed in KATP-GOF islets in 
vivo12,22,34.
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Conversely, reduced insulin content in KATP-KO mouse islets after chronic incubation in either low or high 
glucose suggests that chronic membrane hyperexcitability is a major determinant of insulin loss in vitro. Although 
there is no significant reduction in β-cell mass in normoglycemic KATP-KO mice15,16,35, these results suggest that 
Figure 5. Chronic pharmacologic manipulation of membrane excitability alters insulin content and secretion. 
(a) Insulin content in WT islets incubated for 10 days in 3 mM and 30 mM glucose, or plus the addition of 
the KATP channel inhibitor glibanclamide (1 µM) or the activator diazoxide (250 mM), or insulin (20 nM). 
Significant differences *p < 0.05 with respect to control under the same condition, non-significant are not 
indicated in the figure. Insulin secretion response to acute low (light grey bars) or high (dark grey bars). Glucose 
stimulated insulin secretion on WT islets chronically exposed to low glucose (b) or high glucose (c) plus 
glibenclamide or diazoxide. Significant differences *p < 0.05 with respect to chronic glucose alone under the 
same stimulatory condition, non-significant differences are not indicated in the figures. Inserts represent insulin 
secretion as a fraction of content.
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elevated [Ca2+]i will be detrimental in the setting of hyperglycemia, consistent with studies indicating that high 
[Ca2+]i is a key factor in reduction of β-cell functionality in diabetes15,16,30,31,35.
Is increased membrane excitability, independent of altered metabolism, responsible for 
reduced insulin content?. Consistent with the idea that chronic β-cell hyperexcitability leads to a persis-
tently elevated [Ca2+]i, and insulin hypersecretion with depletion of insulin stores24,36, our in vitro data show that 
increasing membrane excitability, either genetically (KATP-KO islets) or pharmacologically (glibenclamide-treated 
islets), does indeed lead to marked reduction in insulin content over ~3 days. Conversely, islets with genetically 
(KATP-GOF islets) or pharmacologically (diazoxide-treated) reduced membrane excitability maintain insulin con-
tent over the full 10 days, even when they are chronically incubated in high glucose. Persistent inhibition of WT 
KATP channels with glibenclamide induces similar reduction of insulin content to that observed in KATP-KO islets. 
These results correlate with studies demonstrating reduction of GSIS in rodent and human islets chronically 
incubated with sulfonylurea drugs, although these effects have only been observed in vitro, and not with consist-
ency36–38. In addition, these results correlate with our previous observations that, in islets chronically exposed to 
glibenclamide, there is a mild increase in DNA synthesis; an effect that was completely abrogated by the presence 
of nifedipine (a calcium channel inhibitor), arguing that it is indeed driven by elevated [Ca2+]i,39. Moreover, our 
results are also consistent with those showing that islets chronically incubated in, or re-exposed to, sulfonylureas 
exhibited insulin secretion that occurs at lower [glucose] and accompanied by reduction in the maximal insulin 
response40,41.
Preserved insulin content and maintained GSIS (Fig. 4) in WT islets exposed to high glucose in the presence 
of diazoxide mimicked the effect observed in underexcited KATP-GOF islets, supporting the hypothesis that ‘rest’ 
from hyperexcitability and therefore from chronically elevated [Ca2+]i is protective against depletion of insulin 
content, and potentially against Ca2+-dependent apoptosis24,36. WT islets incubated in the presence of high glu-
cose plus diazoxide have been reported to be more glucose sensitive, and to show a left-shift in glucose-stimulated 
insulin secretion, as well as a marked increase in DNA synthesis without changes in plasma KATP channels39,42,43. 
However, changes in β-cell oscillatory [Ca2+]i and KATP conductance and a shift in glucose sensitivity have also 
been reported in islets incubated overnight with high glucose plus diazoxide44 which is consistent with altered 
KATP trafficking to the plasma membrane. Our results also correlate with decreased insulin content and secretion 
in human islets incubated in high glucose for 4 days, effects that were partially reversed by addition of diazoxide 
in the incubation media45.
The concept of deficient insulin stores as a contributing factor to β-cell dysfunction in type-2 diabetes arose 
many years ago, based on the observation that type-2 diabetic patients show restoration of insulin response to oral 
sulfonylurea stimulation after a period of treatment with diazoxide or insulin, in order to induce β-cell ‘rest’46–49. 
Diazoxide treatment has also been shown to improve subsequent β-cell secretory function in 90% pancreatecto-
mized diabetic rats and in streptozotocin-diabetic rats50, and to reverse the marked loss of glucose-induced rise 
in [Ca2+]i in human islets exposed to chronic high glucose51. Taken together, these in vitro and in vivo studies 
implicate electrical excitability-dependent loss of β-cell insulin content in high glucose conditions, which can be 
restored after exposure to low glucose and consequent suppression of excitation. Normally, islets do not accumu-
late large amounts of proinsulin since it is processed into mature insulin, which is then secreted. We began cul-
turing islets from KATP-GOF mice at day 10 post tamoxifen at which point these mice are already hyperglycemic 
(>30 mM blood glucose levels) due to lack of insulin secretion. This will drive enhanced glucose metabolism, and 
since proinsulin biosynthesis is induced in response to glucose metabolism, elevated proinsulin in these islets may 
be expected52. In the KATP-KO model, since insulin is persistently secreted (reflected in accumulation of insulin in 
the media in low glucose condition), proinsulin accumulation is minimal. As expected, when any islets (controls, 
KATP-GOF or KATP-KO) are exposed to chronically high glucose, they showed increased proinsulin synthesis in 
response to elevated glucose in the media.
Figure 6. Changes in proinsulin content in vitro in islsts genetically altered or pharmacologically treated with 
KATP channel inhibitors and activators. (a) Proinsulin content at 0, 3 and 9 days on KATP-WT (black), KATP-KO 
(red) or KATP-GOF (green) islets chronically incubated in low or high glucose. (b) Proinsulin content at 0, 3 and 
9 days on WT islets chronically incubated in low or high glucose with or without the addition of glibencalmide 
(pink) or diazoxide (blue).
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While precise mechanisms underlying the decrease in insulin content are not clear, our finding of increased 
proinsulin in all islets incubated in high glucose is consistent with inefficient conversion of proinsulin to insulin, 
potentially due to chronic glucose-induced oxidative and endoplasmic reticulum stress. It has been shown that, 
while glibenclamide increases and diazoxide decreases insulin secretion, there is no effect of these drugs on 
proinsulin biosynthesis (reviewed in53). These results are consistent with our observations that islets chronically 
incubated in high glucose, whether in the presence of either glibenclamide or diazoxide (which induce oppo-
site effects on excitability and [Ca]i), leads to increased proinsulin, thus highlighting the effect of high glucose 
itself on proinsulin accumulation, rather than membrane excitability per-se. Our results also correlate with those 
demonstrating decreased proinsulin/insulin ratio in human islets treated with diazoxide at 11 mM glucose, which, 
by reducing excitability, preserves insulin content45. In obese mouse models of type-2 diabetes, islet proinsulin 
synthesis is typically increased and is accompanied by decreased mature insulin granules, due to dysfunctional 
insulin processing, effects that are reversed following incubation in low glucose media54. Consistent with the 
findings in rodent islets, human islets exposed to high glucose show accumulation and preferential secretion of 
proinsulin, secondary to depletion of mature insulin granules55.
exogenous insulin prevention of high glucose-induced loss of insulin content. We have previ-
ously demonstrated that inclusion of insulin in the incubation media can protect islets from loss of endogenous 
insulin content39. Preservation of insulin content in WT islets that were co-incubated with high glucose and 
insulin is consistent with studies that demonstrate better preservation of β-cell function in newly diagnosed 
type-2 diabetic patients subjected to intensive insulin therapy than in those treated with sulfonylureas7,46. It has 
also previously been shown that insulin can acutely induce membrane hyperpolarization by activation of KATP 
channels56, although such a mechanism seems unlikely to contribute to the chronic preservation of insulin in the 
current experiments. At higher concentrations, DNA synthesis and islet proliferation can be induced by exoge-
nous insulin39, but this is not likely at the concentration used in the present study.
In vitro versus in vivo models of glucotoxicity. We demonstrate here that chronic membrane hyper-
excitability induced by high glucose conditions underlies loss of insulin content, and that membrane underex-
citability protects islets from high glucose-induced loss of insulin content in vitro. It is important to note that 
pancreatic β-cells from mice with altered membrane excitability show the opposite long-term outcomes in vivo. 
We and others have previously demonstrated a marked reduction of insulin content, β-cell mass and insulin 
mRNA in islets from KATP-GOF diabetic mice with reduced membrane excitability12–14,22,34. This is the result of 
chronic systemic diabetes and correlates with findings demonstrated in other forms of diabetes21,33,57. The primary 
mechanism for loss of insulin was shown to be pancreatic β-cell dedifferentiation to progenitor-like cells in the 
severely diabetic state, with re-differentiation to mature β-cells following lowering of blood glucose by intensive 
insulin therapy22,33. Conversely, islets with chronically increased membrane excitability and increased [Ca2+]i 
(from KATP-KO15,16,18 and KATP-LOF mice20,26) show preserved insulin content in vivo. Moreover, chronic phar-
macologic treatment with glibenclamide leading to increase in membrane excitability did not demonstrate any 
significant reduction in pancreatic islet insulin content in vivo35.
These differences observed in vivo versus in vitro may arise from the shorter duration of exposure to high 
glucose typically examined in vitro, including in this study, which might not be sufficient for the long-term con-
sequences detected in vivo to occur. In addition, the in vitro absence of other nutrients such as amino acids 
and incretin hormones, which are known modulators of β-cell sensitivity to glucose, may contribute to in vivo 
consequences. We previously demonstrated that the in vivo environment is important for the islet response in 
KATP-GOF mice. Severely diabetic KATP-GOF mice show increased glucose metabolism at non-stimulatory glu-
cose concentrations20, whereas KATP-GOF mice treated acutely with glibenclamide at disease onset can enter a 
sustained remission and maintain near normoglycemia34, effects that are characteristic of other animal models of 
β-cell overstimulation and diabetes34,35,58. Finally, it is also important to note that the types of stresses that β-cells 
are exposed to in vitro (e.g. islet isolation from vascularization, loss of endothelial cells, and changes in intracel-
lular matrix) are absent in vivo and could influence the response to high glucose exposure. Thus, other in vivo 
factors could also play a role in the marked loss of drug responsiveness, β-cell function deterioration, reduction 
of insulin content and loss of β-cell mass in diabetes11.
β-cell rest from hypermetabolism, hyperexcitability or hypersecretion? What does ‘rest’ mean 
in potential recovery from β-cell dysfunction?. Finally, there has been much interest in the idea that 
exogenous insulin (and insulin plus diazoxide) treatment leads to β-cell ‘rest’, and that this permits restoration 
of β-cell function. It is unclear exactly what ‘rest’ means in this context: Does it mean rest from hyperstimulated 
metabolism, hyperexcitation, elevated [Ca2+]i, or from insulin secretion? Some studies clearly lean towards rest 
meaning rest from secretion. The present study provides one clear answer: our results show that rest from hyper-
excitability (and its downstream consequences) is the key determinant of maintenance of insulin content in vitro. 
KATP-GOF islets (or WT islets treated with diazoxide), which are permanently in the ‘resting’ state in terms of 
excitability, [Ca2+]i, and insulin secretion maintain insulin content even in the chronic metabolically stimulated 
state of hyperglycemia. Conversely, KATP-KO islets (or WT islets treated with glibenclamide), which are chroni-
cally excited, lose insulin content rapidly in both high and low glucose conditions.
Methods
Mouse models of altered membrane electrical activity. All experiments were performed in compli-
ance with the institutional guidelines of, and approved by, the Washington University Animal Studies Committee. 
KATP knockout16 and tamoxifen-inducible Pdx1PBCreERTM β-cell specific KATP-GOF (Kir6.2 [K185Q, ΔN30])12 
mutant mice were previously generated. Control littermates were used in all experiments.
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pancreatic islet isolation. Mice were anesthetized with Isofluorane (0.2 ml) and killed by cervical dis-
location, and the bile duct was cannulated and perfused with Hank’s solution (Sigma) containing collagenase 
(Collagenase Type XI, Sigma). The pancreas was removed and digested at 37 °C, hand shaken and washed in cold 
Hank’s solution. Islets were isolated by hand under a dissecting microscope and maintained overnight in CMRL-
1066 (5.6 mM glucose) culture medium (GIBCO) supplemented with fetal calf serum (10%), penicillin (100 U/
ml), and streptomycin (100μg/ml)12.
Islet morphology measurements. Following overnight incubation in CMRL media containing 5.6 mM 
glucose, 30 islets per group were chronically incubated for 10 days in CMRL-1066 containing low (3 mM) or high 
(30 mM) glucose (experiment done in triplicates). On day 9, islets images were obtained using the Leica DMI 
4000B inverted microscope (Lecia microsystems, IL) under bright field. Islet mean grey value and islet area were 
analyzed by Fiji (ImageJ).
electrophysiological experiments. Whole cell recordings were made using an Axopatch 200B ampli-
fier and Digidata 1200 (Molecular Devices), as reported previously59. Voltage clamp recordings were performed 
using a ramp protocol from −120 mV to +40 mV with cells held at −70 mV during the inter-pulse interval. The 
bath solution was Tyrode’s solution contained 137 mM NaCl, 5.4 mM KCl, 1 mM MgCl2, 2 mM CaCl2, 0.33 mM 
NaH2PO4, 5 mM HEPES and 1 mM Glucose with pH adjusted to 7.4 mM with NaOH. The pipette solution con-
tained 120 mM KCl, 10 mM HEPES and 1 mM K-EGTA, with pH adjusted to 7.4. For current clamp recordings 
current was held at 0pA. The bath solution used for current clamp recordings contained 10 mM glucose for cells 
from islets chronically incubated in 30 mM glucose and was unaltered for cells from islets chronically incubated 
at 3 mM glucose. Glass electrodes were pulled from Kimble-Chase 2502 plain capillary tubes using a P-87 puller 
(Sutter instruments). For voltage clamp recordings electrodes with 1–3 MΩ tips were used and for current clamp 
recordings 5–7 MΩ tips were used.
Islet manipulation and measurement of insulin secretion and content. 30 islets per group were 
incubated at low (3 mM) or high (30 mM) glucose and were collected at day 3, 6 and 9 for measurement of insu-
lin content. Insulin secreted in the media under 3 and 30 mM glucose conditions was measured on day 3. For 
reversibility experiments, isolated islets were incubated with high glucose for several days and then the media was 
changed to low glucose for the time indicated in the figures. Additionally, wild-type islets were chronically incu-
bated for 10 days in low or high glucose in the presence of 1 μM glibenclamide or 250 µM diazoxide (to block or 
activate KATP, and thereby pharmacologically increase or decrease membrane excitability, respectively), or in the 
presence of 20 nM insulin. After the chronic treatment period, the islets were counted, and then pre-incubated in 
groups of 10 per well in 12 well plates in glucose-free CMRL-1066 plus 3 mM glucose, then incubated for 1 hour 
at 37 °C in CMRL-1066 plus low (3 mM) or high (30 mM) glucose for insulin secretion experiments. After the 
incubation period, the medium was removed and assayed for released insulin. Experiments were repeated in 
triplicate. For islet insulin content, groups of 10 islets were disrupted using ethanol-HCl extraction and sonicated 
on ice for estimation of insulin content. Insulin secretion and content were measured using either Rat Insulin 
radioimmunoassay (RIA, Millipore, St. Charles, MO)22 or Ultrasensitive Mouse Insulin Elisa kit (Crystal Chem, 
Elk Grove Village, IL)60 according to manufacturer’s procedure22.
Measurement of proinsulin content in islets. Islets were incubated overnight in CMRL media contain-
ing 5.6 mM glucose prior to all experiments. On days 0, 3, and 9, replicates of 10 islets per genotype was collected 
in microcentrifuge tubes, washed with PBS and re-suspended in acid-ethanol extraction buffer. Proinsulin con-
tent was calculated by utilizing the Mouse Proinsulin Elisa (Mercodia, Salem NC).
statistics. Data are presented as mean ± SEM. Differences among groups were tested using analysis of var-
iance (ANOVA) and post-hoc Duncan’s test. When only two groups were compared, unpaired t-tests were used 
to assess significance. *Indicates significant differences, with p < 0.05 respect to control condition. **Indicates 
significant differences p < 0.01, ***p < 0.001 and ****p < 0.0001.
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